Bioethics: access to rehab

Claim: Insurers should not be allowed to force patients through "step therapy" (trying cheaper drugs first) when a physician has documented that the required cheaper drug is medically unsuitable; coverage should follow the documented clinical judgment, not a fixed cost ladder.\nEvidence: Step therapy, sometimes called "fail first," requires a patient to try one or more lower-cost medications and show they do not work before the insurer will pay for the drug the doctor originally prescribed. For some conditions this is harmless, but for others (such as certain autoimmune or seizure disorders) making a stable patient switch to a cheaper drug can trigger a relapse or a dangerous flare before the "failure" is officially recorded. Medical guidelines allow exceptions when a physician documents that the cheaper option is contraindicated or has already failed for that patient.\nReasoning: Distributive justice asks who gains and who bears the cost of a rule. A blanket step-therapy requirement lowers cost for the insurer, but it shifts the harm (relapse, side effects, lost time) onto the patient, and it hits hardest those who cannot afford to pay for the correct drug on their own while they "fail first." Respecting a documented physician exception is fairer because it matches the resource to the actual clinical need instead of to a one-size cost ladder, controlling spending in the ordinary case without endangering the patient in the exceptional one.\nCounter-argument I heard and my response: A classmate argued that without step therapy, drug costs and everyone's premiums would climb because doctors would default to the priciest options. That is a real concern, so a fair system can keep step therapy as the general rule but require insurers to grant a fast, documented medical exception. That controls cost in most cases while still protecting the patient whose doctor has shown the cheaper drug is unsafe.